Advertisement

Topics

Shire CEO backs outcomes-based deals in rare diseases

08:32 EST 10 Nov 2017 | pharmaphorum

Rare disease firms will increasingly use payment schemes where health systems are only charged when drugs work, the CEO of specialist pharma Shire has said. Under the leadership of CEO Flemming Ornskov, Shire has transformed itself into the leade...

Original Article: Shire CEO backs outcomes-based deals in rare diseases

NEXT ARTICLE

More From BioPortfolio on "Shire CEO backs outcomes-based deals in rare diseases"

Advertisement
Quick Search
Advertisement
Advertisement